Aspirin Use And The Development Of Cardiac Allograft Vasculopathy In Pediatric Heart Transplant Recipients

Purpose Cardiac allograft vasculopathy (CAV) has limited treatment options and results in significant mortality. Data in adult heart transplant (HTx) recipients suggests that aspirin (ASA) use may reduce the risk of CAV. However, there are limited pediatric data on this topic. This study aimed to assess the use of ASA in pediatric HTx recipients and its association with CAV. Methods All patients in the Pediatric Heart Transplant Society database \u003e 3 years of follow up were included. ASA use during the first 3 years post-transplant was defined as continuous, intermittent, or no ASA use. Time to CAV and graft loss was compared across groups using the Kaplan Meier method. A multivariable survival model was constructed for each outcome to assess the impact of early post-HTx ASA use. Results A total of 3,011 patients were identified for inclusion with 387 (13%) continuous, 676 (22%) intermittent, and 1948 (65%) with no ASA use. ASA use was more common in older patients (p Conclusion ASA use varies widely across pediatric HTx centers. Early ASA use did not reduce the risk of CAV or graft loss.